Calculus Capital’s portfolio company Synpromics, the leading synthetic promoter and gene control company, has announced the expansion of the research collaboration with Adverum Biotechnologies that began in December 2015. The initial collaboration focused on using Synpromics technology to develop promoters for the treatment of eye diseases, and has yielded promising early results.
The new research collaboration announced today, which will be for an initial period of one year, will use Synpromics PromPT™ technology to develop promoters that specifically regulate gene expression in certain types of liver cells. The liver is a major target for gene therapy applications to treat metabolic diseases and where systemic distribution of therapeutic effect is required. It is an ideal organ due to its large size and heavy vascularisation.
Dr David Venables, CEO of Synpromics, commented, “We are delighted to have expanded our relationship with Adverum. In the past year we have clearly demonstrated the power of combining our PromPT™ synthetic promoter technology with Adverum’s platform. We are very excited to be extending the relationship into the area of liver cell gene therapy.”